Sunshine Biopharma Inc.SBFM
Price (close)
$0.80
Market cap
$1.9M
P/E
—
Revenue (TTM)
$35.3M
Net income
-$5.8M
Dividend yield
—
1-year total return
-94.7%
Net margin
-16.5%
Revenue growth
-2.7%
Debt / equity
—
What Sunshine Biopharma Inc. does.
life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We have two wholly owned subsidiaries:
(i) Nora Pharma Inc. (“Nora Pharma”), a Canadian corporation, through which we currently have 71 generic prescription drugs
on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. (“Sunshine Canada”), a Canadian corporation which develops
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $71,410 | $228,426 | $4.3M | $24.1M | $34.9M | $36.3M |
| Net income | -$2.8M | -$12.4M | -$26.7M | -$4.5M | -$5.1M | -$6.0M |
| Free cash flow | -$658,490 | -$1.8M | -$5.4M | -$8.9M | -$14.2M | -$5.5M |
More on SBFM.
- Sunshine Biopharma Inc. summary
- Sunshine Biopharma Inc. financial statements
- Sunshine Biopharma Inc. key metrics
- Sunshine Biopharma Inc. health scores and style box
- Sunshine Biopharma Inc. earnings
- Sunshine Biopharma Inc. dividends
- Sunshine Biopharma Inc. valuation
- Sunshine Biopharma Inc. ownership and insiders
- Sunshine Biopharma Inc. peers
Figures from Sunshine Biopharma Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.